We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.19M
AUM Growth
-$227K
Cap. Flow
+$432K
Cap. Flow %
6.98%
Top 10 Hldgs %
84.83%
Holding
22
New
7
Increased
3
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$730K
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$510K
3
FATE icon
Fate Therapeutics
FATE
+$456K
4
RVMD icon
Revolution Medicines
RVMD
+$448K
5
RCUS icon
Arcus Biosciences
RCUS
+$348K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$703K
2
IQV icon
IQVIA
IQV
+$375K
3
IGMS
IGM Biosciences
IGMS
+$353K
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$322K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$296K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.4B
$755K 12.2%
10,000
-719
-7% -$58.7K
REGN icon
2
Regeneron Pharmaceuticals
REGN
$68.3B
$710K 11.47%
+1,500
New +$730K
FATE icon
3
Fate Therapeutics
FATE
$294M
$660K 10.66%
8,000
+4,760
+147% +$456K
ABBV icon
4
AbbVie
ABBV
$454B
$649K 10.49%
6,000
+1,324
+28% +$142K
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$120B
$645K 10.42%
3,000
-85
-3% -$18.7K
RVMD icon
6
Revolution Medicines
RVMD
$40.1B
$459K 7.42%
+10,000
New +$448K
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$358M
$355K 5.74%
8,000
– –
GRTS
8
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$349K 5.64%
+37,000
New +$510K
TGTX icon
9
TG Therapeutics
TGTX
$8.5B
$337K 5.45%
7,000
+1,153
+20% +$55.4K
ARDX icon
10
Ardelyx
ARDX
$1.27B
$331K 5.35%
+50,000
New +$343K
RCUS icon
11
Arcus Biosciences
RCUS
$3.74B
$281K 4.54%
+10,000
New +$348K
BCEL
12
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$276K 4.46%
+18,000
New +$292K
TDOC icon
13
Teladoc Health
TDOC
$1.56B
$273K 4.41%
1,500
-444
-23% -$103K
ORTX
14
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$109K 1.76%
+1,500
New +$107K
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$35.9B
– –
-2,000
Closed -$260K
BMY icon
16
Bristol-Myers Squibb
BMY
$126B
– –
-11,327
Closed -$703K
IGMS
17
DELISTED
IGM Biosciences
IGMS
– –
-4,000
Closed -$353K
IQV icon
18
IQVIA
IQV
$34.6B
– –
-2,094
Closed -$375K
NBIX icon
19
Neurocrine Biosciences
NBIX
$17.5B
– –
-3,089
Closed -$296K
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-3,740
Closed -$287K
TBIO
21
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-12,091
Closed -$223K
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-2,788
Closed -$322K

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Copernicus Capital Management held 22 positions worth $6.19M, down 3.5% from $6.42M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Copernicus Capital Management deployed $432K of net new capital in Q1 2021, opening 7 new positions and adding to 3 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 1,500 shares worth $710K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Teladoc Health, an estimated $103K trimmed.

  • Copernicus Capital Management's largest Q1 2021 buy was Regeneron Pharmaceuticals: 1,500 shares worth $710K.
  • Copernicus Capital Management added most to Fate Therapeutics in Q1 2021, an estimated $456K increase.
  • Copernicus Capital Management's biggest Q1 2021 reduction was Teladoc Health, cutting an estimated $103K.
  • Copernicus Capital Management fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $703K.
  • Copernicus Capital Management's ten largest holdings make up 85% of its $6.19M portfolio in Q1 2021.
  • Copernicus Capital Management opened 7 new positions and closed 8 in Q1 2021.
  • Copernicus Capital Management's portfolio value fell 3.5% quarter-over-quarter to $6.19M.

Based on Copernicus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.